



RECEIVED

DEC 31 2002
PATENT

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that on December 19, 2002, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner of Patents, Washington, DC 20231.

Trudi Thompson
Trudi Thompson

Applicant: Jolly et al.

Serial No.: 09/001,039

Filed: December 30, 1997

Title: **METHODS FOR ADMINISTRATION OF
RECOMBINANT GENE DELIVERY
VEHICLES FOR TREATMENT OF
HEMOPHILIA AND OTHER DISORDERS**

Examiner: Robert A. Schwartzman

Group Art Unit: 1636

Atty Docket No.: 1155.005 (20263-431)

#37

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RESPONSE TO OFFICE COMMUNICATION

Commissioner for Patents
Washington, D.C. 20231

Sir:

The Examiner has issued an office communication dated November 19, 2002, asserting that the application fails to comply with the requirements of 37 CFR 1.821-1.825. More specifically, the Examiner states that amino acid sequence Ser-Glu-Asn on page 26 and the wild-type sequence in Fig. 41 have not been included in the previously filed sequence listing.

In response, Applicants submit that a sequence listing is not required for the amino acids sequence disclosed on page 26 because 37 CFR 1.821-1.825 only applies to sequences having four or more amino acids. With respect to the wild-type sequence in Fig. 41, Applicants submit that the portion of the wild-type sequence as shown in Fig. 41 is already recited in Seq. ID. No. 45 (see also p. 29). Accordingly, Applicants submit that the sequence listing submitted with the pending application complies with 37 CFR 1.821-1.825.

Respectfully submitted

Louis C. Cullman

Registration No. 39,645

December 19, 2002

CHIRON CORPORATION

Intellectual Property – R 440

P. O. Box 8097

Emeryville, California 94662-8097

Telephone: (510) 923-2719 * Facsimile: (510) 655-3542